Clinical Plan of Ischemic Stroke

Stroke Clinical Trial

Official title:

A Multicenter, Blind, Randomized, Placebo-controlled Phase I / IIA Study to Evaluate the Safety, Tolerability, and Initial Efficacy of a Single Injection of Ischemia Tolerant Human Allogeneic Bone Marrow Mesenchymal Stem Cells in Patients With Ischemic Stroke

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04953663
• Other study ID #: D2020093
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 1, 2021
• Est. completion date: January 1, 2023

Study information

• Verified date: June 2021
• Source: Peking University Third Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells are a kind of pluripotent cells with the ability of self replication. The self-renewal and differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion effect and immune characteristics, provide the possibility for mesenchymal stem cells to treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble media including growth factors and cytokines may be the main mechanism of mesenchymal stem cells.

Description:

Stroke is the main cause of adult health damage. 20% of stroke survivors need institutional care after 3 months, and up to 30% of them have severe or permanent disability. Stem cells are a kind of pluripotent cells with the ability of self replication. The self-renewal and differentiation characteristics of mesenchymal stem cells, as well as cytokine secretion effect and immune characteristics, provide the possibility for mesenchymal stem cells to treat ischemic stroke. After the infusion of mesenchymal stem cells, the secretion of soluble media including growth factors and cytokines may be the main mechanism of mesenchymal stem cells. The main purpose of this study was to evaluate the safety and tolerance of intravenous injection of ischemia tolerant human allogeneic bone marrow mesenchymal stem cells in patients with ischemic stroke. The secondary objective was to evaluate the clinical efficacy of ischemic tolerant human allogeneic bone marrow mesenchymal stem cells in the treatment of ischemic stroke patients with neurological dysfunction.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: January 1, 2023
• Est. primary completion date: January 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male and female = 18 years old;

2. The history showed that the last clinical diagnosis of ischemic stroke was more than 6 months;

3. The results of MRI at the first diagnosis and at the time of selection indicated that there was ischemic stroke and dysfunction;

4. There was no significant improvement in neurological function or functional defect 2 months before the study;

5. There is serious neurological dysfunction related to the diagnosis in Article 2, which leads to the subjects need the assistance of others to walk, or cannot complete the general activities of daily living independently;

6. NIHSS score was 6-20;

7. The life expectancy is more than 12 months;

8. Before treatment, the patient received standard medical care for secondary prevention of ischemic stroke, including but not limited to appropriate blood pressure and cholesterol control measures, use of antiplatelet drugs or anticoagulants (except prohibited cases);

9. Be able to understand and provide the signed informed consent, or ask the designated legal guardian or spouse to make the above decision voluntarily on behalf of the subjects;

10. It is reasonable to expect that patients will receive standard medical care for secondary prevention of ischemic stroke and participate in safety follow-up of all plans;

11. Organ function determined according to the following criteria:

Serum AST = 2.5 × Upper normal limit (ULN);

Serum alanine aminotransferase (ALT) = 2.5 × Normal upper limit;

Total serum bilirubin = 1.5 × Normal upper limit;

In subjects without antithrombotic therapy, prothrombin time (PT) and partial thrombokinase time (PTT) = 1.25 × Normal upper limit;

Serum albumin = 3.0g/dl;

Absolute neutrophil count (ANC) = 1500/ µ L;

Platelets = 150000/ µ L;

Hemoglobin = 9.0g/dl;

Serum creatinine = 1.5 × Normal upper limit;

Serum amylase or lipase were in normal range.

Exclusion Criteria:

1. History of epilepsy;

2. History of tumor;

3. History of brain tumor and brain trauma;

4. hepatitis B, five surface antigens, e antigens, e antibodies and core antibodies were positive for any one, positive for hepatitis C virus antibody, positive for syphilis serum antibody or HIV positive.

5. Myocardial infarction occurred within 6 months before the trial;

6. Suffering from any other medical disease with clinical significance, or with abnormal mental or laboratory results, the researcher or the sponsor determines that participating in the trial will bring safety risks to the subjects;

7. Imaging examination showed subarachnoid hemorrhage or intracerebral hemorrhage in the past 12 months;

8. Participate in another study on the use of test drug or equipment within 3 months before treatment;

9. Participated in other stem cell therapy related research;

10. History of drug or alcohol abuse in the past year;

11. Women who are known to be pregnant, breast-feeding or have a positive pregnancy test (to be tested during the screening process) or plan to be pregnant during the trial;

12. Allergic to cattle and pork products.

Related Conditions & MeSH terms

• Stroke

Intervention

Biological:
• it-hMSC
Different doses of it-hMSC

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijin

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events and serious adverse events rate	Safety and tolerability of it-hMSC treatment	In 12 months
Primary	Rate of clinical significant changes in laboratory	Safety and tolerability of it-hMSC treatment	In 12 months
Primary	Rate of abnormal neurological physical examination results	Safety and tolerability of it-hMSC treatment	In 12 months
Primary	Rate of imaging changes	Safety and tolerability of it-hMSC treatment	In 12 months
Secondary	Change of NIHSS scores	The improvement of neurological function was evaluated by neurological	1?3?6?9?12 months after treatment
Secondary	Change of BI scores	The improvement of neurological function was evaluated by neurological	1?3?6?9?12 months after treatment
Secondary	Change of mRS scores	The improvement of neurological function was evaluated by neurological	1?3?6?9?12 months after treatment
Secondary	Change of MMSE scores	The improvement of neurological function was evaluated by neurological	1?3?6?9?12 months after treatment
Secondary	Change of GDS scores	The improvement of neurological function was evaluated by neurological	1?3?6?9?12 months after treatment